(Pancreatic Cancer) mFOLFIRINOX Improves Disease-Free Survival Better Than Gemcitabine as Adjuvant Therapy
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
As perioperative adjuvant chemotherapy for pancreatic cancer, mFOLFIRINOX improves disease-free survival better than gemcitabine in patients with resectable disease.
On December 20, 2018, the medical journal The New England Journal of Medicine published results from a Phase III clinical trial comparing the efficacy of mFOLFIRINOX combination therapy and gemcitabine in postoperative pancreatic cancer patients.
Adverse events associated with mFOLFIRINOX included diarrhea, sensory disturbance, fatigue, peripheral neuropathy, and vomiting. Gemcitabine was associated with thrombocytopenia. However, based on the statistical results, Dr. Thierry Conroy concluded that mFOLFIRINOX combination therapy improves survival rates in pancreatic cancer patients.
mFOLFIRINOX (oxaliplatin + irinotecan + leucovorin + fluorouracil)
Source: FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer (N Engl J Med, December 20, 2018; 379:2395-2406)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4